Clinical Trial Summary (myeloMATCH)

What is the purpose of this clinical trial?

This trial is the first step in joining a large research study called myeloMATCH. In myeloMATCH, researchers will conduct many different clinical trials for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

This trial is a screening study. It uses biomarker testing to tell the study doctors if they can match you with a myeloMATCH clinical trial for cancer treatment.

A biomarker (sometimes called a marker) is anything about the body that can be measured. In cancer care, specific proteins, genes, and abnormal changes in genes can be important biomarkers. Testing for certain markers can give doctors more information about each patient’s cancer and how to treat it.

The biomarker testing you receive in myeloMATCH has been approved only for use in clinical trials. The tests have not been approved yet for general use outside of the myeloMATCH study.

This trial is set up to find out:

• If you have biomarkers that specific drugs can target in myeloMATCH treatment clinical trials
• How well the process of biomarker testing works to match patients with trials for cancer treatment

Why is this trial important?

Research about cancer biomarkers has led to new treatments that target specific markers. In recent years, targeted drugs have improved treatment options for people with myeloid (blood) cancers.

As new targeted drugs are developed and tested, they are often first only available to patients in clinical trials. The myeloMATCH study is designed to help people access new drugs in clinical trials at all stages of treatment. It will also test recently available drugs to compare them to existing treatments. It aims to speed up the pace of developing targeted treatments for myeloid cancers.

The study is also a chance to improve how new cancer treatments are developed in the future.

Who can be in this trial?

This trial is for adults, age 18 or older, with AML or MDS.

This trial is for people who:

• Have not started treatment for AML or MDS

This trial is not for people who:

• Will need treatment for another cancer while they start treatment for AML or MDS

Talk with your doctor to learn more about who can join this study.

What can I expect during the trial?

If you join this study, researchers will test your bone marrow and blood for specific biomarkers. It will take about 3 days to get your biomarker test results.

If there is a treatment trial that matches your biomarkers, you can choose whether to join that trial.

• You may choose to receive standard treatment instead.
• Talk with your doctor and ask any questions you need to make the right choice for you.

Biomarkers can change. While you are in the study, you can have more biomarker testing to see if your markers match with other myeloMATCH treatment trials.

How long will I be in the trial?

You may stay in myeloMATCH through all stages of your treatment. Even if you receive standard treatments, the researchers will follow how you are doing for 10 years.

Are there costs? Will I get paid?

Biomarker testing is provided free in this study. You will not be paid for joining the study.

Check with your health care provider and insurance provider to find out what costs will and won’t be covered in this study.

Where can I find more information about this trial? 

• Talk with your health care provider 
• Call the National Cancer Institute at 1-800-4-CANCER 
• Go to ClinicalTrials.gov and search the national clinical trial number: NCT05564390
• For a list of trial locations, visit swog.org/NCI-myeloMATCH

Key information

Protocol number: MYELOMATCH
Full trial title: MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
NCT number: NCT05564390
Trial sponsor: SWOG Cancer Research Network
Publishing date: June 2, 2024

Thank you!

When you join a clinical trial, you’re moving cancer medicine and patient care forward. 
 

Download a PDF version of this summary for printing.